Faire Expands to New Zealand and 14 Additional European Countries, Bringing Global Wholesale Platform to Nearly 35 Countries Worldwide
6.8.2025 11:00:00 EEST | Business Wire | Press release
Faire, the leading online wholesale platform, today announced its expansion into New Zealand and 14 additional countries across Europe, making its global network of curated brands and powerful business tools available to independent retailers across nearly 35 countries worldwide. This expansion marks Faire’s broadest international rollout to date and underscores its growing role as the preferred platform for independent retailers and brands worldwide.
Over the past four years, Faire has rapidly expanded across Europe's largest markets, covering 70% of Europe's GDP and becoming a key global partner for independent businesses navigating a complex retail landscape. Today, Europe is growing twice as fast as North America, with brands on the continent fulfilling over 2 million orders on Faire and retailers spending nearly $500 million to date.
“Independent retailers are the heart of local economies around the world, and our mission has always been to help them thrive,” said Max Rhodes, co-founder and CEO of Faire. “This expansion doubles our reach across Europe and extends our community of retailers and brands into New Zealand – giving thousands more shop owners access to the products, tools, and support they need to grow. We’re proud to continue building a global network where local retail can flourish without borders.”
This European expansion includes launches in Croatia, Cyprus, Estonia, Greece, Latvia, Lithuania, Malta, Slovakia, Slovenia, Bulgaria, Czech Republic, Hungary, Poland, and Romania – and comes at a critical time for independent retail communities. Countries like Bulgaria and Romania are among the fastest-growing retail economies in Europe, yet local retailers historically faced barriers to accessing international products and suppliers. With Faire's platform, shop owners in cities like Athens, Krakow, and Ljubljana can now stock curated international goods with the same ease as retailers in Paris or New York. More than 35,000 retailers across these countries have already joined Faire’s waitlist, and brands in these markets have listed over 115,000 products on the platform, signaling a vibrant wholesale ecosystem ready to grow.
Lithuania-based home and accessories brand, Linen Tales, joined the platform in 2019 to reach retailers in new markets. “Faire has helped us reach retailers across the world and their customers love our linen home textiles. New retailers discover us through the platform every week, place their first orders easily, and often come back for more,” said Linen Tales founder, Boris Symulevic. Since then, they’ve achieved over $3 million in order volume and are stocked in nearly 2,000 retailers through the platform. “You should try Faire if you want to discover unique new products for your shop.” With Faire’s continued expansion, brands like Linen Tales can now reach retailers in even more countries, introducing their products to new markets and customers across Europe and beyond.
Faire offers retailers access to over 100,000 brands, flexible 60-day payment terms, simplified logistics, and personalized product recommendations – all designed to make wholesale easier and more efficient. Over the past four years, the company has made major investments in its international operations, including localized currency and VAT support, multi-language capabilities, and a robust shipping and logistics infrastructure. Its European headquarters in the UK continues to grow, with roughly 100 employees supporting customers in multiple languages and markets.
The addition of New Zealand also builds on Faire’s strong performance in Australia, where the company launched in 2022. Since then, the platform has enabled more than 170,000 orders for 4,000 Australian brands, and over 10,000 Australian retailers are transacting on the platform, demonstrating clear demand for Faire in the region. The move into New Zealand strengthens Faire's presence in Oceania and provides Australian brands with expanded regional reach while giving New Zealand retailers access to Faire's global network of suppliers.
As local economies continue to digitize and appetite for cross-border commerce grows, Faire's expansion represents a future where local doesn't mean limited.
About Faire:
Faire is an online wholesale platform used by independent retailers to discover, source, and sell unique products from around the corner and around the world. Faire’s data-driven approach levels the playing field for independent retailers by offering net 60 payment terms and free returns on opening orders, eliminating inventory risk and providing access to capital—key offerings previously only available to the largest retail chains. For brands, the platform provides powerful sales, marketing, and analytics tools, so sellers can simplify their wholesale business and focus on making great products. To date, Faire has facilitated over 10M new connections between brands and retailers on the platform. For more information, visit www.faire.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806417859/en/
Contacts
Charlotte Broadbent
charlotte.broadbent@faire.com
+447850762430
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom